选择性向HER2细胞外域的致癌热点突变
Injin Bang1, Takamitsu Hattori1,2, Nadia Leloup1
1Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Nature chemical biology
|October 22, 2024
概括
研究人员开发了针对癌症中的特定HER2突变 (S310F/Y) 的向抗体. 这些抗体抑制受体二分化,选择性地杀死瘤细胞,提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
背景情况:
- 细胞表面受体细胞外域 (ECD) 中的致癌突变可以作为瘤特异性抗原.
- 人体表皮生长因子受体2 (HER2) 是一种受体氨酸激酶,其ECD中已知有瘤基因突变.
- 开发选择性向突变蛋白质的治疗方法,同时节省野生类型的治疗方法是一个重大挑战.
研究的目的:
- 开发新型抗体,选择性地向HER2 ECD中的常见瘤突变 (S310F和S310Y).
- 研究抗体结合的机制及其对HER2二分化和功能的影响.
- 评估这些抗体在临床前癌症模型中的治疗潜力.
主要方法:
- 组合图书馆查和结构导向设计被用来产生选择性抗体.
- 低温电子显微镜 (cryo-EM) 用于确定HER2突变体和抗体结合复合物的结构.
- 进行了体外和体内测试,以评估抗体介导癌细胞杀死和瘤生长抑制的疗效.
主要成果:
- 成功开发了对HER2 S310F和S310Y突变具有选择性的抗体.
- 结构分析显示,抗体模仿HER2二分化臂,抑制受体二分化.
- 抗体-T细胞参与者在体外表明选择性杀死HER2 S310F驱动的癌细胞,并在体内减少瘤生长.
结论:
- HER2 ECD突变代表了基于抗体的治疗方法的可操作目标.
- 开发的抗体显示出选择性向HER2突变癌症的前景.
- 这些发现支持这些新型抗体疗法的进一步临床开发.
更多相关视频
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
82
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:33Cancer-Critical Genes I: Proto-oncogenes
8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K